

First Quarter 2021 Financial Results May 11, 2021 Bradley Joseph, VP Investor Relations and Corporate Communications



Forward-Looking Statements

Solpadeine

Certain statements in this presentation are "forward-looking statements." These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "forecast," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or the negative of those terms or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control, including: the effect of the novel coronavirus (COVID-19) pandemic and the associated economic downturn and supply chain impacts on the Company's business; the timing, amount and cost of any share repurchases; future impairment charges; customer acceptance of new products; competition from other industry participants, some of whom have greater marketing resources or larger market shares in certain product categories than the Company does; pricing pressures from customers and consumers; resolution of uncertain tax positions, including the Company's appeal of the Notice of Assessment ("NoA") issued by the Irish Office of the Revenue Commissioners ("Irish Revenue") and the Notices of Proposed Adjustment ("NOPAs") issued by the U.S. Internal Revenue Service and the impact that an adverse result in any such proceeding could have on operating results, cash flows and liquidity; potential third-party claims and litigation, including litigation relating to alleged price-fixing in the generic pharmaceutical industry, alleged class action and individual securities law claims, and alleged product liability claims and litigation relating to uncertain tax positions, including the NoA and NOPAs; developments relating to ongoing or future settlement discussions relating to any such claims or litigation; potential impacts of ongoing or future government investigations and regulatory initiatives; potential costs and reputational impact of product recalls and sales halts; the impact of tax reform legislation and healthcare policy; general economic conditions; fluctuations in currency exchange rates and interest rates; the occurrence of any event, change or other circumstance that could delay or prevent the consummation of the sale of the RX business (the "RX sale"), including the risk that any required regulatory approvals may not be obtained within the expected time frame or at all; failure to realize the expected benefits of the RX sale; potential costs or liabilities incurred in connection with the RX sale that may exceed the Company's estimates or adversely affect the Company's business and operations; the consummation and success of other announced acquisitions or dispositions, and the Company's ability to realize the desired benefits thereof; and the Company's ability to execute and achieve the desired benefits of announced cost-reduction efforts, and strategic and other initiatives. An adverse result with respect to our appeal of any material outstanding tax assessments or litigation, could ultimately require the use of corporate assets to pay such assessments, damages from third-party claims, and related interest and/or penalties, and any such use of corporate assets would limit the assets available for other corporate purposes. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended December 31, 2020, as well as the Company's subsequent filings with the United States Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this presentation are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.


Non-GAAP Measures: This presentation contains Non-GAAP measures. The reconciliation of those measures to the most comparable GAAP measures are included at the end of this presentation.



Murray S. Kessler, President & CEO



Our Aggressive Plan to Transform from a Healthcare Company to a Consumer Self-Care Company...





That Started Two Years Ago, is Now Nearing Completion 1 Year Ahead of Schedule

Portfolio Reconfigured	Businesses Revitalized & Returned to Growth	Uncertainty Being Reduced	Poised to Build Value
Selling Generic Rx	 Built \$500MM New Product Pipeline 	 Dialogue Opened with Irish Revenue on Irish Tax Case 	 Perrigo now a Focused CPG story, Certainty Restored
Sold Rosemont RxSold Animal Health	 Launched >\$300M in total Consumer NP's in '19 & '20. 	 Major IRS case to M.A.P. Strengthened Cyber Security 	 3/5/7 Growth Commitment benchmarks to top tier CPG companies
Closed India R&DBought Ranir Oral Care	 Invested \$130M+ in IT & Infrastructure 	Consistently Delivering Financial Commitments	 Favorable Comps in Back Half '21 And Steady Stream
Bought Dr. Fresh	 50%+ Leadership Team Changed Delivering \$100M Cost Savings 	 Divesting Most Volatile Businesses 	of Innovation
 Bought Steripod[®] Bought Prevacid[®] 	Improved Service from 70% to	Strengthened Governance –	 Approx. \$2 Billion in Cash after Rx sale to Further Drive Growth
Bought E. Europe Skin-Care	90%+Successfully Built e-Comm	ESG, D&I	
Bought Dexsil [®] Brand in EU	Platform Built Business Intelligence		
Invested in Kazmira	Capabilities		
	 Delivered 2018-2020 Net Sales⁽¹⁾ CAGR of +7.2% compared to 2015-2018 CAGR of +0.5% 		

Perrigo

1. Net sales excluding divested businesses and currency. See attached Appendix for reconciliation of Adjusted (Non-GAAP) to Reported (GAAP) amounts

As Expected, Q1:21 Results Down Due to Two COVID-19 Driven Reasons

Perrigo Perfo	rmance	Financial Highlights
		 ✓ Organic net sales down 10.9% - impacted by:
Net Sales	\$1.01B	1. an estimated -6.8 percentage
YoY % Change	-6.8%	points from pandemic-related pantry load benefit last year, and
Adjusted Operating Income	\$118M	2. an estimated -6.4 percentage points from lower cough/cold
YoY % Change	-21.6%	sales this year
Adjusted EPS	\$0.50	✓ Adjusted EPS included \$0.30 negative impact from Net Sales Drivers above,
YoY % Change	-25.4%	partially offset by A&P savings, Acquisitions and Project Momentum savings


1. See attached Appendix for details.

2. Organic net sales growth excludes the effects of acquisitions and divestitures and the impact of currency.

3. In addition to other non-GAAP adjustments as described in the attached appendix, adjusted profit measures, including adjusted EPS and adjusted operating income, exclude from both periods certain costs, which are reported in GAAP continuing operations but were previously allocated to the RX business. On a go-forward basis, such costs will either be covered by the transition services agreement or eliminated following closing. We do not believe such operational costs are representative of the future expenses of our continuing operations. See attached appendix for additional details.




Entire Quarterly Decline Occurred in March As We Lapped 2020 COVID-19 Related Demand Surge





Importantly, Business Remains Strong As Evidenced by 2-Yr Net Sales CAGR +4.1%, Even With Historically Weak Cough/Cold Season



Organic net sales growth excludes the effects of acquisitions, divestitures and the impact of currency. See attached appendix.


Q1 Impacted by Cold/Cough & Prior Year Demand Surge; 2-yr Net Sales CAGRs Strong: CSCA +4.9% and CSCI +2.6%

CSCA	CSCI
-8.6% Reported NS Growth Q1YoY	-3.4% Reported NS Growth Q1YoY
-11.8% Organic	-9.1% Organic
Reported Net Sales Growth 2-Yr CAGR	Reported Net Sales Growth 2-Yr CAGR
CSCA +4.9%	CSCI +2.6%
Cough/Cold Impact -3.6%	Cough/Cold Impact -6.1%
CSCA Ex-Cough/Cold +8.5%	CSCI Ex-Cough/Cold +8.7%
Organic Net Sales Growth 2-Yr CAGR	Organic Net Sales Growth 2-Yr CAGR
CSCA Organic +0.8%	CSCI Organic -2.9%
Cough/Cold Impact -3.3%	Cough/Cold Impact -5.4%
CSCA Organic Ex- Cough/Cold +4.1%	CSCI Organic Ex- Cough/Cold +2.5%




. Organic net sales growth excludes the effects of acquisitions, divestitures and the impact of currency. See attached appendix

While Weak Cough/Cold Was The Result Of Record Low Flu Levels in the U.S. and Europe Due To COVID-19 Related Lock-downs...




Source: *IQVIA FAN data ending 3/27/21; **Flu News Europe – World Health Organization Data ending 3/31/21.

That Is Not Expected To Continue; IQVIA FAN Data Predicting **Elevated Cough/Cold Heading into Spring/Summer**



igo

In Fact, IQVIA Estimates 'Normalized' 2021/22 Season; Perrigo Estimates Partial Recovery, Which Supports Strong 2021 Second Half Estimates



 — — Mid Range 2021/2022 CC Season Illness Projections

Actual Illness Levels



Source: IQVIA FAN data.

Perrigo 2021 New Product Launches Also Support Strong Second Half Forecasts



BURT'S BEES® Licensing Agreement

Offer a comprehensive line of organic baby formulas and innovative nature-based remedies under the iconic Burt's Bees[®] brand

 Combines Perrigo's R&D, regulatory, and sales & marketing capabilities with Burt's Bees[®] distinctive brand and deep understanding of the efficacy of nature-based ingredients to care for baby and mom, to create organic and innovative naturebased remedies



14

While H2 Operating Income is More Heavily Weighted, This Reflects 'Back to Normal' Pre-COVID-19 Earnings Phasing

Adjusted Operating Income Phasing

	<u>H1</u>	<u>H2</u>
2019 Actual	44%	56%
2020 Actual	52%	48%
2021 Projected	~44%	~56%

Other Phasing Considerations

- Perrigo estimating 2021/22 Cough/Cold Illnesses will be Between Normal 2019/20 and Historically Weak 2020/21 Season
- E-commerce Growth Continues
- New Product Launch Timing
- A&P Redistributed to Pre-COVID-19 Media Priorities and Timing



Therefore, Perrigo is Reaffirming its Guidance from Continuing Operations

Adjusted EPS Guidance Range: \$2.50 to \$2.70, +7% YoY



- +5% Adjusted Operating Income Growth vs. 2020
- 2021 Adjusted Effective Tax Rate of 23%
- 134MM Shares Outstanding

Upside with ~\$2B in Cash on Hand After Rx Transaction Close

- Disciplined M&A
- De-lever Balance Sheet
- Stock Buyback



Perrigo Transformed – A Growing, Pure-Play Consumer Self-Care Company with Significant Upside Optionality



- Focused, pure-play consumer company
- Strong balance sheet with ~\$2B in pro forma cash
- Making progress with reducing uncertainty
- Highly defensible business model
- Differentiated in the marketplace
- Well diversified across categories and geographies
- Durable business fundamentals



Ray Silcock, EVP & CFO



Continuing Operations Summary – Q1:2021

Consolidated					Restructuring, Impairment						
3 Months Ending April 3, 2021					Charges, and			Income from			
(in millions, except per share amounts)				DSG&A	Other Operating	Operating	Interest	continuing operations before	Income Tax	Income from continuing	Diluted Earnings per
(Unaudited)	Net Sales	Gross Profit	R&D Expense	Expense	Income	Income	and Other	income taxes	Expense	operations*	Share*
Reported	\$1,010.0	\$368.4	\$31.1	\$284.2	\$1.7	\$51.4	\$34.4	\$17.0	\$14.2	\$2.8	\$0.02
As a % of reported net sales		36.5%	3.1%	28.1%	0.2%	5.1%	3.4%	1.7%	1.4%	0.3%	
Effective tax rate									84.0%		
Pre-tax adjustments:											
Amortization expense related primarily to acquired intangible assets		\$23.0	(\$0.5)	(\$32.1)		\$55.6	(\$1.2)	\$56.8		\$56.8	\$0.43
Acquisition and integration-related charges and contingent consideration adjustments				(\$0.8)		\$0.8		\$0.8		\$0.8	\$0.01
(Gain) loss on divestitures				\$0.0		\$0.0	(\$0.4)	\$0.4		\$0.4	
Unusual litigation				(\$3.4)		\$3.4		\$3.4		\$3.4	\$0.03
Restructuring charges and other termination benefits				\$0.0	(\$1.7)	\$1.7		\$1.7		\$1.7	\$0.01
RX transitional business costs**		\$0.6	(\$0.1)	(\$4.9)		\$5.6		\$5.6		\$5.6	\$0.04
Non-GAAP tax adjustments***									\$4.8	(\$4.8)	(\$0.04)
Adjusted	\$1,010.0	\$392.0	\$30.5	\$243.0		\$118.5	\$32.8	\$85.7	\$19.0	\$66.7	\$0.50
As a % of reported net sales		38.8%	3.0%	24.1%		11.7%	3.2%	8.5%	1.9%	6.6%	
Adjusted effective tax rate									22.2%		

Diluted weighted average shares outstanding

Reported

134.6M

Perrigo

*Individual pre-tax line item adjustments have not been tax effected, as tax expense on these items are aggregated in the "Non-GAAP tax adjustments" line item.

**Includes costs which are reported in continuing operations but were previously allocated to the RX business. On a go-forward basis, such costs will either be covered by the transition services agreement or eliminated following closing. Accordingly, we do not believe such operational costs are representative of the future expenses of our continuing operations.

***The non-GAAP tax adjustments of \$4.8 million are primarily due to: (1) \$13.6 million of tax expense related to pre-tax non-GAAP adjustments calculated based upon their jurisdictional income tax rates and (2) removal of \$8.8 million tax expense related to non-recurring intra-entity transfers of intellectual property and valuation allowance releases in the U.S.



Adjusted Gross Profit Adjusted Gross Margin % Adjusted Operating Income	Q1 2021	YoY \$ Change	Organic % Change
Net Sales	\$1.0B	(\$73M)	(10.9%)
Adjusted Gross Profit	\$392M	(\$24M)	
Adjusted Gross Margin %	38.8%	40 bps	
Adjusted Operating Income	\$118M	(\$33M)	
Adjusted Operating Margin %	11.7%	(230) bps	

- 1. Organic net sales growth excludes the effects of acquisitions, divestitures and the impact of currency. See attached appendix.
- 2. In addition to other non-GAAP adjustments as described in the attached appendix, adjusted profit measures, including adjusted EPS and adjusted operating income, exclude from both periods certain costs, which are reported in GAAP continuing operations but were previously allocated to the RX business. On a go-forward basis, such costs will either be covered by the transition services agreement or eliminated following closing. We do not believe such operational costs are representative of the future expenses of our continuing operations. See attached appendix for additional details.



20

CSC Americas	Q1 2021	YoY \$ Change	Organic % Change
Net Sales	\$641M	(\$60M)	(11.8%)
Adjusted Gross Profit	\$201M	(\$19M)	
Adjusted Gross Margin %	31.4%	Flat	
Adjusted Operating Income	\$111M	(\$27M)	
Adjusted Operating Margin %	17.3%	(230) bps	

- 1. Organic net sales growth excludes the effects of acquisitions, divestitures and the impact of currency. See attached appendix.
- 2. In addition to other non-GAAP adjustments as described in the attached appendix, adjusted profit measures, including adjusted EPS and adjusted operating income, exclude from both periods certain costs, which are reported in GAAP continuing operations but were previously allocated to the RX business. On a go-forward basis, such costs will either be covered by the transition services agreement or eliminated following closing. We do not believe such operational costs are representative of the future expenses of our continuing operations. See attached appendix for additional details.



CSC International	Q1 2021	YoY \$ Change	Organic % Change
Net Sales	\$370M	(\$13M)	(9.2%)
Adjusted Gross Profit	\$191M	(\$6M)	
Adjusted Gross Margin %	51.6%	30 bps	
Adjusted Operating Income	\$60M	(\$4M)	
Adjusted Operating Margin %	16.3%	(40) bps	

- 1. Organic net sales growth excludes the effects of acquisitions, divestitures and the impact of currency. See attached appendix.
- 2. In addition to other non-GAAP adjustments as described in the attached appendix, adjusted profit measures, including adjusted EPS and adjusted operating income, exclude from both periods certain costs, which are reported in GAAP continuing operations but were previously allocated to the RX business. On a go-forward basis, such costs will either be covered by the transition services agreement or eliminated following closing. We do not believe such operational costs are representative of the future expenses of our continuing operations. See attached appendix for additional details.



Select Balance Sheet & Liquidity Measures	4/3/2021	12/31/2020
Total Company Cash & Cash Equivalents	\$481M	\$642M
Total Debt	\$3.6B	\$3.6B
Net Debt	\$3.1B	\$2.9B





APPENDIX

TABLE I PERRIGO COMPANY PLC RECONCILIATION OF NON-GAAP MEASURES SELECTED CONSOLIDATED INFORMATION (in millions, except per share amounts) (unaudited)

				Т	Three Months E	nded April	3, 2021					
Consolidated Continuing Operations	Net Sales	Gross Profit	R&D Expense	DSG&A	Restructuring, Impairment Charges, and Other Operating Income	Operating Income	Interes and Oth		Income Tax Expense	Income from continuing operations	Ea	Diluted arnings per Share*
Reported	\$1,010.0	\$ 368.4	\$ 31.1	\$ 284.2	\$ 1.7	\$ 51.4	\$ 34.4	4	\$ 14.2	\$ 2.8	\$	0.02
As a % of reported net sales		36.5 %	3.1 %	28.1 %	0.2 %	5.1 %	6 3.4	4 %	1.4 %	0.3 %	6	
Effective tax rate									84.0 %			
Pre-tax adjustments:												
Amortization expense related primarily to acquired intangible assets		\$ 23.0	\$ (0.5)	\$ (32.1)	\$ —	\$ 55.6	\$ (1.2	2)	\$ —	\$ 56.8	\$	0.43
Acquisition and integration-related charges and contingent consideration adjustments		_	_	(0.8)	_	0.8	_	_	_	0.8		0.01
(Gain) loss on divestitures		_	_	_	—	_	(0.4	4)	_	0.4		_
Unusual litigation		_	_	(3.4)	—	3.4	_	_	_	3.4		0.03
Restructuring charges and other termination benefits		_	_	_	(1.7)	1.7	_	_	_	1.7		0.01
Indirect RX business support costs***		0.6	(0.1)	(4.9)	_	5.6	_	_	_	5.6		0.04
Non-GAAP tax adjustments**		_	_	_	_	_	_	_	4.8	(4.8)		(0.04)
Adjusted		\$ 392.0	\$ 30.5	\$ 243.0	\$ —	\$ 118.5	\$ 32.8	8	\$ 19.0	\$ 66.7	\$	0.50
As a % of reported net sales		38.8 %	3.0 %	5 24.1 %		11.7 %	6 3.2	2 %	1.9 %	6.6 %	6	
Adjusted effective tax rate									22.2 %			
			Diluted w	eighted ave	erage shares ou	utstanding						
			Reported	I								134.6

*Individual pre-tax line item adjustments have not been tax effected, as tax expense on these items are aggregated in the "Non-GAAP tax adjustments" line item.

**The non-GAAP tax adjustments are primarily due to: (1) \$13.6 million of tax expense related to pre-tax non-GAAP adjustments calculated based upon their jurisdictional income tax rates and (2) removal of \$8.8 million tax expense related to non-recurring intra-entity transfers of intellectual property and valuation allowance releases in the U.S.

***Includes certain costs, which are reported in GAAP continuing operations but were previously allocated to the RX business. On a go-forward basis, such costs will either be covered by the transition services agreement or eliminated following closing. Accordingly, we do not believe such operational costs are representative of the future expenses of our continuing operations.



TABLE I (CONTINUED) PERRIGO COMPANY PLC RECONCILIATION OF NON-GAAP MEASURES SELECTED CONSOLIDATED INFORMATION (in millions, except per share amounts) (unaudited)

					Thr	ee Mon	ths	s Ended M	Marc	ch 28, 20)20					
Consolidated Continuing Operations	Net Sales	Gross Profit		R&D pense		SG&A		perating ncome	Otl Ch Fi	iterest, her, and ange in nancial Assets	I	ncome Tax xpense	cc op	Income from ontinuing perations	Ea	iluted rnings per hare*
Reported	\$ 1,083.3	\$ 393.7	\$	27.9	\$ 2	279.4	\$	86.4	\$	29.0	\$	(0.2)	\$	57.6	\$	0.42
As a % of reported net sales		36.3 %	, D	2.6 %)	25.8 %)	8.0 %		2.7 %	, D	—%	0	5.3 %)	
Effective tax rate) (0.4%				
Pre-tax adjustments:																
Amortization expense primarily related to acquired intangible assets Acquisition and integration-related charges and contingent consideration adjustments		\$ 21.6	\$	(0.2)	\$	(28.9) (2.0)	\$	50.7 2.0	\$	_	\$	_	\$	50.7 2.0	\$	0.37 0.01
Change in financial assets						(2.0)		2.0		1.6				(1.6)		(0.01)
-		_		_		(0,7)		0.7		1.0		_		0.7		0.01
Separation and reorganization expense		_		_		(0.7)		-		_		_		-		
Unusual litigation				_		(4.5)		4.5						4.5		0.03
(Gain) Loss on investment securities		—						_		(3.0)		—		3.0		0.02
Indirect RX business support costs***		1.0		(0.2)		(5.7)		6.9		_				6.9		0.05
Non-GAAP tax adjustments**						_		—		_		32.1		(32.1)		(0.23)
Adjusted		\$ 416.3	\$	27.5	\$ 2	237.6	\$	151.2	\$	27.6	\$	31.9	\$	91.7	\$	0.67
As a % of adjusted net sales		38.4 %	, D	2.5 %)	21.9 %	•	14.0 %		2.5 %	, D	2.9 %)	8.5 %)	
Adjusted effective tax rate												25.8 %)			
							Di	luted wei	ight	ed avera	age	shares	out	standing		
							Re	eported								137.3

*Individual pre-tax line item adjustments have not been tax effected, as tax expense on these items are aggregated in the "Non-GAAP tax adjustments" line item.

**The non-GAAP tax adjustments are primarily due to: (1) \$16.3 million of additional tax expense related to pre-tax non-GAAP adjustments calculated based upon their applicable jurisdictional income tax rates and (2) removal of \$15.8 million tax benefit related to the U.S. CARES Act retroactive adjustments to prior tax years.

***Includes certain costs, which are reported in GAAP continuing operations but were previously allocated to the RX business. On a go-forward basis, such costs will either be covered by the transition services agreement or eliminated following closing. Accordingly, we do not believe such operational costs are representative of the future expenses of our continuing operations.



TABLE II PERRIGO COMPANY PLC RECONCILIATION OF NON-GAAP MEASURES SELECTED SEGMENT INFORMATION (in millions)

(unaudited)

					/Ionths ril 3, 20		ded			Three Months Ended March 28, 2020											
Consumer Self-Care Americas	Net Sales		ross rofit		R&D kpense)SG&A xpense		perating ncome		Net Sales		Gross Profit	E	R&D xpense)SG&A xpense		perating ncome		
Reported	\$ 640.5	\$ 1	94.5	\$	19.7	\$	78.8	\$	95.6	\$	700.6	\$ 2	213.8	\$	17.9	\$	73.8	\$	122.1		
As a % of reported net sales		;	30.4 %	•	3.1 %	6	12.3 %	, D	14.9 %				30.5 %	, D	2.6 %	5	10.5 %	ó	17.4 %		
Pre-tax adjustments:																					
Amortization expense related primarily to acquired intangible assets		\$	6.1	\$	(0.1)	\$	(6.7)	\$	12.9			\$	5.0	\$	_	\$	(6.7)	\$	11.6		
Restructuring charges and other termination benefits			_		_		_		0.4						_		_		_		
Acquisition and integration-related charges and contingent consideration adjustments							(0.8)		0.8								(1.0)		1.9		
			_		_		(0.8)		0.8						_		(1.9)		1.9		
Indirect RX business support costs*			0.6		(0.1)		(0.1)		0.8				1.0		(0.3)		(0.5)		1.8		
Adjusted		\$ 2	01.2	\$	19.5	\$	71.2	\$	110.5			\$2	219.8	\$	17.6	\$	64.7	\$	137.4		
As a % of reported net sales		:	31.4 %	•	3.0 %	6	11.1 %	, D	17.3 %				31.4 %	, D	2.5 %	5	9.2 %	ó	19.6 %		

*Includes certain costs, which are reported in GAAP continuing operations but were previously allocated to the RX business. On a go-forward basis, such costs will either be covered by the transition services agreement or eliminated following closing. Accordingly, we do not believe such operational costs are representative of the future expenses of our continuing operations.

	Three Months Ended April 3, 2021							Three Months Ended March 28, 2020									
Consumer Self-Care International	:	Net Sales		Gross Profit	E	R&D Expense	DSG&A Expense	-	Operating Income		Net Sales	Gross Profit		R&D xpense	DSG&A Expense	-	Dperating Income
Reported	\$	369.5	\$	173.9	\$	11.4	\$ 145.1	\$	17.4	\$	382.7	\$ 179.9	\$	10.0	\$ 144.8	\$	25.0
As a % of reported net sales				47.1 %	6	3.1 %	39.3 %	6	4.7 %			47.0 %	6	2.6 %	37.8 %	6	6.5 %
Pre-tax adjustments:																	
Amortization expense related primarily to acquired intangible assets			\$	16.9	\$	(0.4)	\$ (25.4)	\$	42.7			\$ 16.6	\$	(0.1)	\$ (22.1)	\$	39.0
Adjusted			\$	190.8	\$	11.0	\$ 119.7	\$	60.1	-		\$ 196.5	\$	9.9	\$ 122.7	\$	64.0
As a % of reported net sales				51.6 %	6	3.0 %	32.4 %	6	16.3 %			51.3 %	6	2.6 %	32.1 %	6	16.7%



TABLE II (CONTINUED) PERRIGO COMPANY PLC RECONCILIATION OF NON-GAAP MEASURES SELECTED CONSOLIDATED INFORMATION (in millions, except per share amounts) (unaudited)

	Six Months Ended													
Consolidated Continuing Operations Operating Income		lune 29, 2019	De	cember 31, 2019		June 27, 2020	De	ecember 31, 2020						
Reported	\$	82.0	\$	120.2	\$	163.7	\$	129.4						
Pre-tax adjustments:														
Amortization expense primarily related to acquired intangible assets Acquisition and integration-related charges and contingent consideration adjustments	\$	108.3 (1.9)	\$	115.3 18.1	\$	101.5 6.9	\$	108.3 5.7						
Separation and reorganization expense		12.5		4.7		0.7		0.4						
Impairment charges		4.1		9.7		_		_						
(Gain) loss on divestitures		_		(4.5)		0.3		0.5						
Operating results attributable to held-for-sale business*		(3.5)		1.3		—		—						
Asset Abandonment		_		7.1		_		_						
Unusual litigation		16.1		11.1		9.0		10.8						
Restructuring charges and other termination benefits		21.5		4.5		0.7		2.5						
Ranitidine market withdrawal**		_		18.4		_		_						
Adjusted	\$	239.1	\$	305.9	\$	282.8	\$	257.6						
		44 %	6	56 %	, D	52 %	6	48 %						

*Held-for-sale business includes our now divested animal health business.

**Ranitidine market withdrawal includes reversal of recorded returns and inventory write-downs.



TABLE III PERRIGO COMPANY PLC RECONCILIATION OF NON-GAAP MEASURES ADJUSTED NET SALES GROWTH - SELECTED SEGMENTS (in millions)

(unaudited)

	 Three Mor	nths	Ended			
	April 3, 2021		March 28, 2020	Total Change	FX Change	Constant Currency Change
Reported Net sales						
Consolidated Continuing Operations	\$ 1,010.0	\$	1,083.3	(6.8)%		
CSCA	\$ 640.5	\$	700.6	(8.6)%		
CSCI	\$ 369.5	\$	382.7	(3.4)%		
Consolidated Continuing Operations	\$ 1,010.0	\$	1,083.3			
Less: Rosemont Pharmaceuticals business	 		(14.3)			
Consolidated Continuing Operations net sales as so adjusted excluding divested businesses	\$ 1,010.0	\$	1,069.0	(5.5)%	(2.4)%	(7.9)%
Less: Dr. Fresh*	(25.1)		_			
Less: Eastern European Brands Acquisition	(7.2)		—			
Organic Consolidated Continuing Operations net sales as so adjusted	\$ 977.7	\$	1,069.0	(8.5)%	(2.4)%	(10.9)%
CSCA	\$ 640.5	\$	700.6			
Less: Dr. Fresh*	(23.8)		_			
Organic CSCA net sales as so adjusted	\$ 616.7	\$	700.6	(12.0)%	0.2%	(11.8)%
CSCI	\$ 369.5	\$	382.7			
Less: Rosemont Pharmaceuticals business	_		(14.3)			
CSCI net sales as so adjusted excluding divested businesses	\$ 369.5	\$	368.4	0.3%	(7.1)%	(6.8)%
Less: Dr. Fresh*	(1.3)		_		()	
Less: Eastern European Brands Acquisition	(7.2)		_			
Organic CSCI net sales as so adjusted	\$ 361.0	\$	368.4	(2.0)%	(7.1)%	(9.1)%

*Dr. Fresh acquisition comprises all oral self-care assets purchased from High Ridge Brands, including the brands Dr. Fresh®, REACH® and Firefly®.



TABLE III (CONTINUED) PERRIGO COMPANY PLC RECONCILIATION OF NON-GAAP MEASURES ADJUSTED NET SALES GROWTH - SELECTED SEGMENTS (in millions)

(unaudited)

		Three Mon	ths	Ended		
	March 30, 2019			April 3, 2021	2019-2021 Change	2019-2021 CAGR
Reported Net sales						
Consolidated Continuing Operations	\$	932.6	\$	1,010.0	\$ 77.4	4.1%
Less: Cough, cold, and flu product sales*		(134.2)		(69.2)		
Consolidated Continuing Operations as so adjusted	\$	798.4	\$	940.8	\$ 142.4	8.6%
Consolidated Continuing Operations	\$	932.6	\$	1,010.0		
Less: Animal Health		(19.6)		_		
Less: Infant foods		(5.3)		_		
Less: Canoderm prescription product		(3.7)		_		
Less: Rosemont Pharmaceuticals business		(13.1)		_		
Less: Ranir		_		(71.0)		
Less: Dr. Fresh		_		(25.1)		
Less: Eastern European Brands Acquisition		_		(7.2)		
FX impact**		_		(23.8)		
Consolidated Continuing Operations organic net sales as so adjusted - constant currency	\$	890.9	\$	882.9	\$ (8.0)	(0.4)%
Less: Cough, cold, and flu product sales*		(134.2)		(69.2)		
Organic Consolidated Continuing Operations as so adjusted-constant currency	\$	756.7	\$	813.7	\$ 57.0	3.7%

*Includes sales of certain products in our upper respiratory and pain and sleep aids (primarily children's analgesic products) categories which are typically used to treat cough, cold and flu illnesses.

**Converted 2021 net sales in currencies other than USD at 2019 Q1 average FX rate for comparable presentation to 2019.



TABLE III (CONTINUED) PERRIGO COMPANY PLC RECONCILIATION OF NON-GAAP MEASURES ADJUSTED NET SALES GROWTH - SELECTED SEGMENTS (in millions)

(unaudited)

	Three Mor	nths	Ended		
	arch 30, 2019		April 3, 2021	2019-2021 Change	2019-2021 CAGR
Reported Net sales	 			 	
CSCA	\$ 581.8	\$	640.5	\$ 58.7	4.9%
Less: Cough, cold, and flu product sales*	(66.9)		(34.5)		
CSCA net sales as so adjusted	\$ 514.9	\$	606.0	\$ 91.1	8.5%
CSCA	\$ 581.8	\$	640.5		
Less: Animal Health	(19.6)		_		
Less: Infant foods	(5.3)		_		
Less: Ranir	_		(49.9)		
Less: Dr. Fresh	_		(23.8)		
FX impact**	_		(1.0)		
Organic CSCA net sales as so adjusted - constant currency	\$ 556.9	\$	565.8	\$ 8.9	0.8%
Less: Cough, cold, and flu product sales*	(66.9)		(34.5)		
Organic CSCA net sales as so adjusted - constant currency	\$ 490.0	\$	531.3	\$ 41.3	4.1%
Reported Net sales					
CSCI	\$ 350.8	\$	369.5	\$ 18.7	2.6%
Less: Cough, cold, and flu product sales*	(67.3)		(34.7)		
CSCI net sales as so adjusted	\$ 283.5	\$	334.8	\$ 51.3	8.7%
CSCI	\$ 350.8	\$	369.5		
Less: Canoderm prescription product	(3.7)		_		
Less: Rosemont Pharmaceuticals business	(13.1)		_		
Less: Ranir	_		(21.1)		
Less: Dr. Fresh	_		(1.3)		
Less: Eastern European Brands Acquisition			(7.2)		
FX impact**	_		(25.0)		
Organic CSCI net sales as so adjusted - constant currency	\$ 334.0	\$	314.9	\$ (19.1)	(2.9)%
Less: Cough, cold, and flu product sales*	(67.3)		(34.7)		
Organic CSCI net sales as so adjusted - constant currency	\$ 266.7	\$	280.2	\$ 13.5	2.5%

*Includes sales of certain products in our upper respiratory and pain and sleep aids (primarily children's analgesic products) categories which are typically used to treat cough, cold and flu illnesses.

**Converted 2021 net sales in currencies other than USD at 2019 Q1 average FX rate for comparable presentation to 2019.

TABLE III (CONTINUED) PERRIGO COMPANY PLC RECONCILIATION OF NON-GAAP MEASURES ADJUSTED NET SALES GROWTH - SELECTED SEGMENTS (in millions)

(unaudited)

		Adjusted Net Sales Twelve Mo	- Co nth						
	 December 31, 2015	 December 31, 2016		December 31, 2017		December 31, 2018	20	015-2018 Change	Adjusted Constant Currency 2015-2018 CAGR
Consolidated Continuing Operations									
Reported Net Sales	\$ 3,845	\$ 4,087	\$	3,836	\$	3,811	\$	(34)	(0.3)%
Sales related to VMS business	(162)	(110)		—		—			
Sales related to CSCI exited businesses ⁽¹⁾	(229)	(242)		(32)		—			
Pro-forma Omega ⁽¹⁾⁽²⁾	260	—		—		—			
Pro-forma other acquisition ⁽¹⁾⁽³⁾	86	—		—		—			
Sales related to Animal Health	(154)	(144)		(141)		(94)			
Sales related to Infant foods	(29)	(34)		(32)		(34)			
Sales related to Rosemont Pharmaceuticals business ⁽¹⁾	(64)	(66)		(60)		(57)			
Sales related to Nordics ⁽¹⁾	(11)	(11)		(13)		(15)			
FX impact ⁽¹⁾	19	39		31		—			
Adjusted Net Sales - Constant Currency	\$ 3,561	\$ 3,519	\$	3,589	\$	3,611	\$	50	0.5%

(1) Converted 2015-2017 and adjustments made in currencies other than USD at 2018 average FX rate for comparable presentation to 2018.

(2) Omega acquired 3/31/2015; annualized 2015 for comparable presentation to 2018.

(3) Includes GlaxoSmithKline Consumer Healthcare product portfolio and Naturwohl Pharma GmbH acquired in September 2015; annualized 2015 for comparable presentation to 2018.

	 Adjuste	et Sales - Constant C velve Months Ended	urre	ency		
	December 31, 2018	December 31, 2019		December 31, 2020	2018-2020 Change	Adjusted Constant Currency 2018-2020 CAGR
Consolidated Continuing Operations						
Reported Net Sales	\$ 3,811	\$ 3,870	\$	4,088	\$ 277	3.6%
Sales related to Animal Health	(94)	(44)		—		
Sales related to Infant foods	(34)	(6)		—		
Sales related to Rosemont Pharmaceuticals business ⁽¹⁾	(57)	(53)		(29)		
Sales related to Nordics ⁽¹⁾	(15)	(13)		—		
FX impact ⁽¹⁾	 	 84		90		
Adjusted Net Sales - Constant Currency	\$ 3,611	\$ 3,838	\$	4,149	\$ 538	7.2%

(1) Converted 2019-2020 and adjustments made in currencies other than USD at 2018 average FX rate for comparable presentation to 2018.



TABLE IV

PERRIGO COMPANY PLC

RECONCILIATION OF NON-GAAP MEASURES

(in millions, except per share amounts)

(unaudited)

	 Three Months Ended								
	April 3, 2021	N	larch 28, 2020	Total Change					
Consolidated Continuing Operations adjusted EPS	\$ 0.50	\$	0.67	(25.4)%					
Adjusted gross profit									
CSCI	\$ 190.8	\$	196.5	(2.9)%					
Adjusted gross margin									
Consolidated Continuing Operations	38.8 %		38.4 %	40 bps					
CSCA	31.4 %		31.4 %	— bps					
CSCI	51.6 %		51.3 %	30 bps					
Adjusted operating income									
Consolidated Continuing Operations	\$ 118.5	\$	151.2	(21.6)%					
Adjusted operating margin									
Consolidated Continuing Operations	11.7 %		14.0 %	(230) bps					
CSCA	17.3 %		19.6 %	(230) bps					
CSCI	16.3 %		16.7 %	(40) bps					



TABLE V PERRIGO COMPANY PLC **REPORTED NET SALES BY PRODUCT CATEGORY** (in millions)

(unaudited)

	Three Months Ended						
		April 3, 2021	Ν	March 28, 2020			
CSCA ⁽¹⁾							
Upper respiratory	\$	114.0	\$	154.6			
Digestive health		113.5		106.9			
Pain and sleep-aids		92.4		120.4			
Nutrition		92.0		102.2			
Healthy lifestyle		75.5		85.8			
Oral self-care		73.7		55.3			
Skincare and personal hygiene		53.3		46.7			
Vitamins, minerals, and supplements		7.8		6.4			
Other CSCA ⁽²⁾		18.3		22.3			
Total CSCA		640.5		700.6			
CSCI							
Skincare and personal hygiene		107.0		94.7			
Vitamins, minerals, and supplements		59.0		48.5			
Healthy lifestyle		50.3		43.6			
Pain and sleep-aids		49.0		46.8			
Upper respiratory		42.9		84.1			
Oral self-care		25.5		23.2			
Digestive health		8.5		6.0			
Other CSCI ⁽³⁾		27.3		35.8			
Total CSCI		369.5		382.7			
Total net sales	\$	1,010.0	\$	1,083.3			

(1) Includes net sales from our OTC contract manufacturing business.

(2) Consists primarily of diagnostic products and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.
 (3) Consists primarily of our distribution business and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.

